Analystreport

Reata Pharmaceuticals, Inc. (NASDAQ: RETA) had its price target lowered by analysts at Cantor Fitzgerald from $230.00 to $112.00. They now have an "overweight" rati

Reata Pharmaceuticals, Inc. - Class A  (RETA) 
Last reata pharmaceuticals, inc. - class a earnings: 2/19 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.reatapharma.com